Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 23, 2017. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $42.28 per ADS
- Transaction Volume: 4 ADSs
Material Changes
The filing reports an increase of 4 ADSs held by Dr. K. Slaoui, a PCA of Dr. M. M. Slaoui (Chairman, Global Vaccines). This increase resulted from the notional allocation of ADSs on March 22, 2017, due to the revaluation of the cash element of a notional investment within the GSK 401(K) plan. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of an insider transaction.
Key Facts for Investor Verification
- Verify the identity of Dr. K. Slaoui and their relationship to Dr. M. M. Slaoui.
- Confirm the transaction date of March 22, 2017, and the price of $42.28 per ADS.
- Note that the transaction volume (4 ADSs) is nominal and driven by a 401(K) plan revaluation, not an open market purchase.
- Understand that this filing does not contain quarterly or annual financial performance data.